Minhua Chu, Managing Partner at TransitionValue Partner, shared a post on X:
“Suzhou Ribo Life Science announced the successful completion of its Series E financing round, raising over RMB 200 million (approximately $28 million). The round was led by Mingxin Capital.
Ribo is a biotech focus on siRNA therapies with R&D centers in Suzhou, Beijing (China) and Gothenburg (Europe).
Pipeline.”
More post featuring Minhua Chu on OncoDaily.
